stockportfolio.pro
Stocks / EVMN vs OMER
EVMN vs OMER
Evommune, Inc. and Omeros Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Evommune, Inc. (EVMN) | Omeros Corporation (OMER) | |
|---|---|---|
| Market cap | $0.7B | $0.7B |
| Revenue (latest FY) | $13.00M | $0 |
| Net income (latest FY) | $-68.87M | $-3.35M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | -529.8% | — |
| Return on equity | -33.5% | 2.8% |
| P/E ratio | — | 9.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open EVMN — free Open OMER — freeFrequently asked questions
Which is bigger, EVMN or OMER?
Evommune, Inc. is larger by market capitalization — $0.7B versus $0.7B.
Which grows faster, EVMN or OMER?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.